TCRT — Alaunos Therapeutics, Inc.

Summary of Alaunos Therapeutics Q1 2023 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: Approximately $10 million for Q1 2023, or $0.04 per share, compared to a net loss of $9.8 million or $0.05 per share in Q1 2022.
• R&D Expenses: Increased to $6.5 million from $5.6 million year-over-year, primarily due to heightened manufacturing and TCR discovery activities.
• G&A Expenses: Decreased to $3.2 million from $3.5 million, reflecting lower professional fees.
• Cash Position: Total cash balances as of March 31, 2023, were approximately $37.4 million, including a release of $13.9 million in restricted cash following the repayment of a term loan with Silicon Valley Bank.
• Operating Cash Burn: Approximately $9.4 million for Q1 2023, up from $7.8 million in Q1 2022, aligning with increased manufacturing activities.

2. Strategic Updates and Business Highlights

• Clinical Trials: Progress in the TCR-T library Phase 1/2 trial, with accelerated patient enrollment and enhancements to screening and manufacturing processes. The trial targets six solid tumor indications.
• IND Amendments: Implemented changes to streamline patient enrollment, including eliminating the requirement for retesting tumor mutations and adding cryopreservation to the manufacturing process.
• Hunter Platform: Ongoing expansion of the proprietary TCR discovery platform, aiming to increase the library from 12 to 15 TCRs, enhancing the addressable market for therapies.
• Corporate Developments: Amended agreement with Precigen to eliminate royalties and milestone obligations, potentially saving over $160 million, and welcomed Robert Hoffmeister to the Board of Directors.

3. Forward Guidance and Outlook

• Clinical Milestones: Expect to treat between 9 and 12 patients by the end of 2023 to complete the Phase 1 portion of the trial, with interim results anticipated in Q3 2023.
• Cash Runway: Projected operating cash outflows for 2023 are between $35 million to $40 million, with sufficient cash resources expected to last into Q4 2023.

4. Bad News, Challenges, or Points of Concern

• Cash Dependency: The timing of the interim data release in Q3 is closely aligned with the cash runway, raising concerns about the need for financing if results are not favorable.
• Enrollment Target: Clarification on patient enrollment targets indicated no change, but the initial impression of a lower target compared to previous guidance raised questions among analysts.
• Market Conditions: While investor engagement is positive, the company remains cautious about dilution and is exploring financing options.

5. Notable Q&A Insights

• ASCO Presentation: While specific efficacy data for the third patient treated will not be disclosed until the ASCO meeting, the company is optimistic about the data being presented.
• Patient Dosing: The interim update in Q3 will include multiple patients, but specifics on the number of patients at different dose levels remain undisclosed.
• Manufacturing Capacity: The company has successfully increased manufacturing capacity and is exploring hybrid approaches for scaling up as it prepares for Phase 2 trials.
• Partnership Opportunities: The Hunter platform's success in TCR discovery is seen as a potential avenue for attracting partnerships and non-dilutive funding.

Overall, Alaunos Therapeutics is making significant strides in its clinical programs and corporate structure, but faces challenges related to cash management and the need for positive interim results to support future financing.